EU/3/19/2173

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2173 was granted by the European Commission to Myelo Therapeutics GmbH, Germany, for imidazolyl ethanamide pentandioic acid (also known as Myelo001) for the treatment of acute radiation syndrome.

Key facts

Active substance
Imidazolyl ethanamide pentandioic acid
Disease / condition
Treatment of acute radiation syndrome
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2173

Sponsor's contact details

Myelo Therapeutics GmbH
Kastanienallee 56
10119 Berlin
Germany
Tel. +49 (0)170 9126 402
E-mail: info@myelotherapeutics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating